Subclinical hypothyroidism, weight change, and body composition in the elderly: the Cardiovascular Health Study.

ORIGINAL E n d o c r i n e

ARTICLE C a r e

Subclinical Hypothyroidism, Weight Change, and Body Composition in the Elderly: The Cardiovascular Health Study Margaret C. Garin, Alice M. Arnold, Jennifer S. Lee, Russell P. Tracy, and Anne R. Cappola Division of Endocrinology, Diabetes, and Metabolism (M.C.G., A.R.C.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104; Department of Biostatistics (A.M.A.), University of Washington, Seattle, Washington 98155; Division of Endocrinology, Gerontology, and Metabolism (J.S.L.), Stanford University School of Medicine and Veterans Administration Palo Alto Health Care System, Palo Alto, California 94305; and Departments of Pathology and Biochemistry (R.P.T.), University of Vermont, Burlington, Vermont 05405

Background: Subclinical hypothyroidism is common in the elderly, yet its relationship with weight and body composition is unclear. Objective: We examined the relationship between subclinical hypothyroidism and weight change and body composition in older adults. Methods: A total of 427 subclinically hypothyroid and 2864 euthyroid U.S. individuals ⱖ65 years old enrolled in the Cardiovascular Health Study and not taking thyroid preparations were included. Analyses of 6-year weight change were performed, compared by thyroid status. A cross-sectional analysis of thyroid status and body composition was performed in a subset of 1276 participants who had dual-energy x-ray absorptiometry scans. Models were risk factor-adjusted and stratified by sex. Results: Overall, participants lost weight during follow-up (⫺0.38 kg/y in men, ⫺0.37 kg/y in women). Subclinical hypothyroidism, when assessed at a single time point or persisting over 2 years, was not associated with a difference in weight change compared with euthyroidism. Subclinical hypothyroidism was also not associated with differences in lean mass, fat mass, or percent fat compared with euthyroidism. A TSH level 1 mU/L higher within the euthyroid or subclinical hypothyroid range was associated with a 0.51-kg higher baseline weight in women only (P ⬍ .001) but not with weight change in either sex. A 1 ng/dL higher free T4 level was associated with lower baseline weight and 0.32 kg/y greater weight loss in women only (P ⫽ .003). Baseline weight and weight change did not differ by T3 levels. Conclusions: Our data do not support a clinically significant impact of subclinical hypothyroidism on weight status in the elderly. (J Clin Endocrinol Metab 99: 1220 –1226, 2014)

ubclinical hypothyroidism in the elderly is of unclear clinical significance, with inconsistent findings across observational studies and a lack of consensus regarding treatment (1). Frequently, patients with overt hypothyroidism complain of weight gain, and treatment of overt hypothyroidism may result in modest weight loss

S

(2). However, the association between subclinical hypothyroidism and weight is less well characterized, especially in the elderly. Obesity is an increasingly concerning global health problem associated with increased morbidity and a shortened life span (3–5). The strength of association between higher weight and mortality is weaker in the elderly (6,

ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A. Copyright © 2014 by the Endocrine Society Received September 24, 2013. Accepted January 3, 2014. First Published Online January 16, 2014

Abbreviations: BMI, body mass index; CHS, Cardiovascular Health Study; CI, confidence interval; DXA, dual-energy x-ray absorptiometry; FT4, free T4; GEE, generalized estimating equation.

1220

jcem.endojournals.org

J Clin Endocrinol Metab, April 2014, 99(4):1220 –1226

doi: 10.1210/jc.2013-3591

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 May 2014. at 14:40 For personal use only. No other uses without permission. . All rights reserved.

doi: 10.1210/jc.2013-3591

7), and other measures of adiposity such as lean and fat mass may be better predictors of mortality risk in this population. It has been suggested in studies of middle-aged adults that subclinical hypothyroidism and higher TSH within the euthyroid range are related to higher weight and body mass index (BMI) (8 –12) or higher fat mass (13, 14). However, several studies in middle-aged adults have found that higher T3 levels in euthyroid or subclinically hypothyroid patients are also related to higher weight and BMI (8, 12, 14, 15), suggesting that thyroid hormoneinduced changes in metabolic rate may not explain the relationship between subclinical hypothyroidism and weight. This calls into question the direction of causality between subclinical thyroid disease and body composition. Few studies have evaluated subclinical hypothyroidism and weight in the elderly, and no studies of older participants were longitudinal or included assessments of T3 and free T4 (FT4) levels. The Cardiovascular Health Study (CHS) is a large cohort study of community-dwelling individuals aged 65 years and older that included both subclinically hypothyroid and euthyroid participants. Using data from the CHS, we sought to assess the relationship between thyroid function and weight change and body composition in an elderly population.


1221

with abnormal TSH levels at the 1994/1995 visit. Thyroid function assays were performed at the CHS Central Blood Analysis Laboratory at the University of Vermont using chemiluminescent immunoassays on the Elecsys 2010 analyzer (Roche Diagnostics). TSH concentrations were measured with a third-generation assay with a functional sensitivity of 0.005 mU/L and 2.1% intra-assay and 3.1% interassay coefficients of variation. The FT4 assay had a functional sensitivity of 0.23 ng/dL (2.96 pmol/L) and 1.7% intra-assay and 3.3% interassay coefficients of variation. A reference range of 0.7 to 1.7 ng/dL (9 –22 pmol/L) was used. The total T3 assay had a functional sensitivity of 19.5 ng/dL (0.3 nmol/L), reference range of 84.4 to 201.3 ng/dL (1.3– 3.1 nmol/L), and 4.2% intra-assay and 4.7% interassay coefficients of variation.

Assessment of outcome variables Anthropometric measures were performed by trained personnel using standardized protocols. Standing height was measured at the 1992/1993 visit using a stadiometer calibrated in centimeters. Weight was measured annually through 1999 using a balance-beam scale calibrated in kilograms. BMI was calculated as weight in kilograms divided by height in meters squared. Dual-energy x-ray absorptiometry (DXA) was performed in 1994 and 1995 at the Pennsylvania and California sites only. Whole-body DXA scans were obtained using Hologic QDR2000 densitometers (Hologic, Inc). Blinded radiologists read the scans at the University of California, San Francisco, Reading Center using Hologic software version 7.10.

Assessment of covariates

Subjects and Methods Study population The CHS is a population-based, longitudinal study of 5888 adults aged 65 and older (16). Enrollment of the original cohort of 5201 adults occurred between May 1989 and June 1990, and an additional cohort of 687 African Americans was enrolled in 1992 and 1993. Eligible individuals were identified from an ageand sex-stratified random sample of the Medicare eligibility rosters in four U.S. communities: Washington County, Maryland; Allegheny County, Pennsylvania; Sacramento County, California; and Forsyth County, North Carolina. To be eligible, individuals had to be noninstitutionalized, expecting to remain in the area for the following 3 years, not in active treatment for cancer, not wheelchair-bound at home, not requiring a proxy respondent at entry, and capable of providing medical consent. Household members of the sampled individuals were recruited, if eligible. The institutional review boards of all 4 sites and the coordinating center at the University of Washington in Seattle approved the study. All participants gave informed consent. Annual study visits through 1999 included a detailed medical history, physical examination, and assessment of health status. Blood was drawn after a 12-hour fast, and serum was processed and stored in ⫺70°C freezers for future testing.

Thyroid function testing Serum TSH was measured in 2009 and 2010 from banked samples from both cohorts obtained at the 1992/1993 (n ⫽ 3996) and 1994/1995 (n ⫽ 4005) visits. FT4 and total T3 were measured in all participants at the 1992/1993 visit and in those

Thyroid medication use was assessed annually via examination of medication bottles. Covariates assessed at the 1992/1993 visit included age, race, smoking status (never, former, or current), kilocalories per week of self-reported physical activity, and self-reported health.

Statistical analysis Characteristics of participants who were not taking thyroid hormone preparations and were either subclinically hypothyroid (TSH 4.51–19.99 mU/L with normal FT4) or euthyroid (TSH 0.45– 4.50 mU/L) in 1992/1993 were compared using ␹2 or t tests. Generalized estimating equations (GEEs) with an exchangeable correlation structure were used to examine the relationship between thyroid status in those who were subclinically hypothyroid or euthyroid at a single time point (the 1992/1993 visit) and annual weight change through the 1998/1999 visit, in participants who had at least 1 additional weight measurement during follow-up. In additional analyses, GEEs were used to analyze the relationship between continuous measures of TSH, FT4, and total T3 and annual weight change in the combined group of subclinically hypothyroid and euthyroid individuals at the 1992/ 1993 visit. Weight change through 1998 and 1999 was also analyzed using GEEs in those who were euthyroid or subclinically hypothyroid at both 1992/1993 and 1994/1995 visits (persistently euthyroid or persistently or transiently subclinically hypothyroid). Linear regression was used to assess the relationship between the change in TSH and change in weight between the 1992/1993 and 1994/1995 visits, excluding subjects with changes in TSH of more than 10 mU/L. Scatterplots were used to display the association. All analyses were adjusted for age, race, smoking, activity level, self-reported health, and thyroid hor-


1222

Garin et al

Subclinical Hypothyroidism and Weight Change

mone initiation and were sex-stratified unless otherwise noted. Because thyroid hormone initiation could be influenced by thyroid and weight status, analyses were repeated without adjustment for thyroid hormone initiation. Participants who were not taking thyroid hormone preparations and were either subclinically hypothyroid (n ⫽ 118) or euthyroid (n ⫽ 1158) in 1994/1995 were included in analyses of body composition by DXA (lean body mass, absolute and percent total body fat, and arm and trunk fat). Cross-sectional associations were examined using linear regression to compare individuals with subclinical hypothyroidism with those with euthyroidism and to analyze continuous measures of TSH and associations with DXA outcomes. Analyses were adjusted for age, race, smoking, activity level, and self-reported health and were sex-stratified.

Results Of the 3996 participants with TSH in 1992 and 1993, 3789 were in the euthyroid or subclinical hypothyroid range and 3520 remained after excluding participants taking thyroid medications. An additional 229 participants did not have at least 2 measurements of weight at the 1992/1993 visit or beyond and were excluded, leaving 3291 in the analysis. Slightly fewer had T3 (n ⫽ 3248) or FT4 (n ⫽ 3268) measurements. There were 427 with subclinical hypothyroidism (268 women and 159 men) and 2864 who were euthyroid (1623 women and 1241 men) (Table 1). Compared with euthyroid women, women with subclinical hypothyroidism were more likely to be Caucasian but were otherwise similar. Subclinically hypothyroid men were slightly older, more likely to be Caucasian, and less likely to have ever smoked than euthyroid men. FT4 levels were lower in those with subclinical hypothyroidism, whereas total T3 levels were slightly higher in women with subclinical hypothyroidism compared with their euthyroid counterparts. Sixty-four (2.2%) of the euthyroid participants and 105 (24.6%) of the


subclinically hypothyroid participants initiated thyroid medications during follow-up. Overall, women experienced an average annual weight loss of 0.37 kg/y and men experienced an average annual weight loss of 0.38 kg/y over 6 years of follow-up. Annual weight change did not differ between subclinically hypothyroid and euthyroid individuals in adjusted models (women, loss of 0.35 vs loss of 0.38 kg/y, P ⫽ .63; men, loss of 0.34 vs loss of 0.38 kg/y, P ⫽ .48; Table 2). A 1 mU/L higher TSH was associated with a 0.51-kg higher baseline weight in women (P ⬍ .001) with no difference in men and no association between TSH as a continuous measure and weight change in either sex (Table 2). Baseline total T3 had no association with baseline weight or weight change. A 1 ng/dL higher FT4 was associated with a 4.60-kg lower baseline weight in women (P ⫽ .005) and a 0.32-kg greater annual weight loss (P ⫽ .003) in women only. Results were unchanged in analyses without adjustment for thyroid hormone initiation (Supplemental Table 1, published on The Endocrine Society’s Journals Online website at http://jcem.endojournals.org). Those participants who were stably euthyroid (n ⫽ 2165), stably subclinically hypothyroid (n ⫽ 191), or transiently subclinically hypothyroid (n ⫽ 123) over a 2-year period were included in an additional analysis. Average annual weight change did not differ between persistently or transiently subclinically hypothyroid and persistently euthyroid women or men in adjusted analyses (women, loss of 0.34 and 0.45 vs loss of 0.46 kg/y, P ⫽ .24; men, loss of 0.49 and 0.41 vs loss of 0.52 kg/y, P ⫽ .79) (Table 3). Twenty-eight (1.3%) of the participants who were persistently euthyroid in 1994 and 1995, 13 (10.6%) of those who were transiently subclinically hypothyroid, and 52 (27.2%) of those who were persistently subclinically hy-

Table 1. Characteristics of Study Sample at Baseline (1992/1993)a Women

TSH, mU/L Age, y Caucasian Activity level, kcal Ever smoker Good to excellent self-reported health BMI, kg/m2 T3, ng/dL FT4, ng/dL

Men

Subclinical Hypothyroid, n ⴝ 268

Euthyroid, n ⴝ 1623

Subclinical P Hypothyroid, Value n ⴝ 159

Euthyroid, n ⴝ 1241

P Value

6.7 (2.6) 74.9 (5.3) 240 (89.6) 675 (226 –1481) 106 (39.6) 219 (81.7) 27.1 (5.3) 1.86 (0.36) 1.07 (0.17)

2.2 (1.0) 74.4 (5.1) 1291 (79.5) 735 (245–1725) 700 (43.1) 1288 (79.4) 26.8 (5.3) 1.80 (0.34) 1.21 (0.17)

NA .11 ⬍.001 .64b .27 .37 .48 .009 ⬍.001

2.1 (0.92) 74.7 (5.3) 1041 (83.9) 1117 (430 –2375) 900 (72.5) 1001 (80.7) 26.7 (3.8) 1.77 (0.30) 1.23 (0.17)

NA .001 .028 .89b .028 .27 .59 .24 ⬍.001

6.7 (2.6) 76.1 (5.7) 144 (90.6) 1072 (547–2102) 102 (64.1) 134 (84.3) 26.6 (3.8) 1.74 (0.28) 1.10 (0.17)

Abbreviations: IQR, interquartile range; NA, not available. a

Data are expressed as number (percentage), except for age, TSH, T3, and FT4, which are expressed as mean (SD) and activity level, which is expressed as median (IQR). NA indicates comparisons not performed due to selection of groups based on this measure.

b

According to t test of mean difference on the natural log scale.


doi: 10.1210/jc.2013-3591


1223

Table 2. Association of Thyroid Function in 1992/1993 With Average Annual Change in Weight Through 1998/1999a

Average weight change/y Euthyroid Subclinical hypothyroid TSH, effect per mU/L Initial weight Average annual weight changec T3, effect per ng/dL Initial weight Average annual weight changec FT4, effect per ng/dL Initial weight Average annual weight changec

Womena

P Value

Mena

P Value

⫺0.38 (⫺0.42 to ⫺0.34) ⫺0.35 (⫺0.45 to ⫺0.26)

.63b

⫺0.38 (⫺0.43 to ⫺0.34) ⫺0.34 (⫺0.46 to ⫺0.21)

.48b

0.51 (0.24 to 0.79) 0.01 (⫺0.01 to 0.03)

⬍.001 .23

0.03 (⫺0.30 to 0.36) 0.01 (⫺0.01 to 0.04)

.86 .18

1.19 (⫺0.50 to 2.89) ⫺0.03 (⫺0.13 to 0.07)

.17 .58

0.52 (⫺1.60 to 2.63) 0.10 (⫺0.03 to 0.24)

.63 .13

⫺4.60 (⫺7.79 to ⫺1.40) ⫺0.32 (⫺0.53 to ⫺0.11)

.005 .003

⫺2.91 (⫺6.40 to 0.58) ⫺0.09 (⫺0.32 to 0.14)

.10 .45

a

Adjusted for age, race, kilocalories of activity (natural log), smoking status, self-reported health, and initiation of thyroid medication use. Results are shown as kg (95% CI). b

For whether slope differs significantly from that in the euthyroid group.

c

Change in slope per unit change in biomarker, given an average estimated slope of ⫺0.37 in women and ⫺0.38 in men.

pothyroid started thyroid medication during follow-up. Results were unchanged in analyses without adjustment for thyroid hormone initiation (Supplemental Table 2). Concurrent changes in TSH and weight from 1992/ 1993 to 1994/1995 could be assessed in 1169 men and 1579 women who were not taking thyroid preparations at either visit, after the removal of 9 participants with absolute changes of ⬎10 mU/L. The average 2-year change in TSH was modest, with a mean (SD) of ⫺0.08 (1.00) mU/L in men and ⫺0.21 (1.19) mU/L in women. The unadjusted association of change in TSH with change in weight appeared linear (Figure 1). In an adjusted linear regression model, a 1 mU/L change in TSH was associated with a 0.27-kg (95% confidence interval [CI], 0.05– 0.48 kg) increase in weight in men (P ⫽ .014) and a 0.18-kg (95% CI, 0.03– 0.34 kg) increase in weight in women (P ⫽ .019). Characteristics of the subgroup of 1276 participants who had DXA scans performed at the 1994/1995 visit are described in Supplemental Table 3. Similar to the overall cohort, men and women with subclinical hypothyroidism were slightly older and more likely to be white compared with those with euthyroidism. Subclinical hypothyroid-

ism was not associated with lean body mass, fat mass, or percent body fat in this subgroup (Table 4). In women, a 1 mU/L higher TSH level within the normal or subclinical hypothyroid range was associated with a 0.46-kg higher total fat mass (P ⫽ .02), 0.038-kg higher mean arm fat (P ⫽ .03), 0.28-kg higher trunk fat (P ⫽ .006), and 0.31% higher percent fat (P ⫽ .04) but not with trunk to arm fat ratio or lean body mass (Table 4). No associations were seen between TSH level and body composition in men.

Discussion In this large population-based study of adults aged 65 years or older, we report no difference in weight trajectory between those with subclinical hypothyroidism and euthyroid individuals, even in those with persistent subclinical hypothyroidism over 2 years. In addition, BMI, lean body mass, and fat mass were not significantly higher in men and women with subclinical hypothyroidism than in their euthyroid counterparts. These findings are particularly relevant in light of previous data from CHS demonstrating

Table 3. Average Annual Weight Change from 1994/1995 to 1998/1999 by Persistence of Thyroid Groups Determined From Measurements in 1992/1993 and 1994/1995a Women

Euthyroid Transient Persistent subclinical hypothyroid

Men

n

Estimated Annual Weight Change, kg (95% CI)

P Value

1224 83 118

⫺0.46 (⫺0.52 to ⫺0.40) ⫺0.45 (⫺0.68 to ⫺0.23) ⫺0.34 (⫺0.54 to ⫺0.14)

.93b .24b

n

Estimated Annual Weight Change, kg (95% CI)

P Value

941 40 73

⫺0.52 ( ⫺0.59 to ⫺0.46) ⫺0.41 (⫺0.73 to ⫺0.10) ⫺0.49 (⫺0.74 to ⫺0.23)

.51b .77b

a

Adjusted for age, race, kilocalories of activity (ln), smoking status, self-reported health, and initiation of thyroid medications.

b

For difference in rate of change from the euthyroid group.


1224

Garin et al


−30

2 year change in weight, kg −20 −10 0 10

20

Men

−10

−5

0 2 year change in TSH, mU/L

5

10

5

10

−30

2 year change in weight, kg −20 −10 0 10

20

Women

−10

−5

0 2 year change in TSH, mU/L

Figure 1. Scatterplots of change in weight vs change in TSH over a 2-year follow-up in men and women.

that thyroid hormone initiation was higher in individuals whose BMI was above 25 kg/m2 (17), a group in whom weight management may influence prescription of thyroid hormone medication. To our knowledge, there are only 4 other studies that


evaluated the association between thyroid status in the euthyroid and subclinically hypothyroid range and anthropometric measures in older participants. None of these studies were longitudinal in design or evaluated FT4 or T3 levels, but their cross-sectional associations with subclinical hypothyroidism are congruent with our null findings (18 –21). A larger body of data exists in middleaged adults, in whom TSH within the euthyroid range has been found to be positively related to weight and BMI in most (8 –12, 22–29), but not all (15, 30) studies. Three of these studies examined weight longitudinally (9, 10, 31). Fox et al (10) failed to find a relationship between baseline TSH within the euthyroid range and weight change, but all 3 studies found a positive association between change in TSH and change in weight or BMI over time. One recent study found no difference in BMI between euthyroid and subclinically hypothyroid participants (32). In addition, 2 studies of middle-aged adults assessed the relationship between TSH and body composition. In a British study of euthyroid subjects, TSH was positively associated with percent body fat measured by electrical bioimpedance (13). In a Greek study of euthyroid men and women, sc fat by ultrasound was positively associated with TSH only in univariate analysis but not in the fully adjusted model (14). Several studies have assessed serum T4 or T3 levels in relation to weight or BMI in middle-aged subjects, although a consistent pattern of associations has not emerged. FT4 has been shown to have no association (12, 14, 22–24, 30) or an inverse relationship (15) with BMI, and FT3 has been shown to have no association (22) or to be positively associated (12, 14) with BMI in euthyroid subjects. In a Danish study of euthyroid and subclinically hypothyroid subjects, FT4 but not FT3 was inversely related to BMI (8). In a longitudinal study, higher FT3 and

Table 4. Association of Thyroid Function With Body Composition (1994/1995) in Subset of Subjects With DXAa

Entries are the differences in the subclinical hypothyroid group compared with the euthyroid group Total fat mass, kg Total lean mass, kg Percent fat, % TSH (mU/L) Entries are the regression estimates for 1 mU/L higher TSH Total fat mass, kg Total lean mass, kg Percent fat, % Mean arm fat, kg Trunk fat, kg Trunk fat/mean arm fat a

Women, n ⴝ 695

P Value

Men, n ⴝ 581

P Value

1.1 (⫺1.2 to 3.5) 0.40 (⫺0.85 to 1.7) 0.86 (⫺0.97 to 2.7)

.34 .53 .36

1.0 (⫺1.3 to 3.3) ⫺0.52 (⫺2.4 to 1.3) 0.97 (⫺0.99 to 2.9)

.39 .58 .33

0.46 (0.08 to 0.84) 0.19 (⫺0.01 to 0.39) 0.31 (0.02 to 0.60) 0.038 (0.005 to 0.071) 0.28 (0.08 to 0.48) 0.056 (⫺0.01 to 0.12)

.02 .07 .04 .03 .006 .095

0.19 (⫺0.13 to 0.51) ⫺0.01 (⫺0.26 to 0.24) 0.13 (⫺0.14 to 0.40) 0.015 (⫺0.008 to 0.037) 0.084 (⫺0.12 to 0.29) ⫺0.022 (⫺0.12 to 0.08)

.24 .94 .35 .20 .42 .65

Adjusted for age, race, kilocalories of activity (ln), smoking status, and self-reported health.


doi: 10.1210/jc.2013-3591

FT4 were each associated with greater risk of becoming obese over a 6-year follow-up (33). Overall, the differences in weight, BMI, and fat mass within the subclinically hypothyroid and euthyroid range found in our study and other published studies in elderly and middle-aged adults were small. Although many studies showed statistically significant relationships between thyroid status and anthropomorphic measures, apart from the results in women found in one study (10), the magnitudes of the differences were modest and of questionable clinical relevance. Furthermore, it is unclear whether treatment of thyroid status within the subclinical and euthyroid ranges would result in meaningful improvements in body composition in overweight patients. The direction of causality in the relationship between thyroid status and weight and body composition is not known. An association between resting energy expenditure and FT4 has been demonstrated in 18 euthyroid male volunteers (34), and lower thyroid function within the subclinical and euthyroid range could lead to weight gain, possibly through a decreased metabolic rate (8). However, patients with subclinical hypothyroidism in randomized trials who are treated with levothyroxine do not show significant weight loss (35, 36). Even in overtly hypothyroid patients, treatment inconsistently affects weight (2, 13). It has been shown that the decrease in body weight seen in overtly hypothyroid patients who initiate levothyroxine is due to excretion of excess body water (37). Conversely, it has been suggested that adipose tissue may affect thyroid function, as evidenced by studies that demonstrate decreases in TSH with weight loss (38, 39). This association between weight loss and TSH is proposed to be mediated by leptin. In times of energy excess, rising levels of leptin are hypothesized to stimulate TSH and increase T4 to T3 conversion (40). In individual analyses of TSH, FT4, and total T3, sexspecific differences were found, with stronger associations of thyroid function tests with weight and body composition in women than in men. This was not due to lower power secondary to fewer men with subclinical hypothyroidism in the cohort, because the effect sizes were smaller in men. Four previous studies found similar sex-specific differences in middle-aged participants, with stronger associations between TSH and weight or BMI in women than in men (9, 10, 24, 26), whereas 3 others showed no sex-specific differences (11, 12, 31). Between-sex differences in leptin and resting fat oxidation have been described in older people (41, 42), although the role that differential effects from thyroid hormone plays in these observations is unknown. A major strength of our study is the use of a large population-based cohort of older men and women with a 6-year longitudinal follow-up of weight. FT4 and T3 were


1225

collected in addition to TSH, allowing accurate categorization of participants as subclinically hypothyroid and for use in separate analyses. All thyroid function testing was performed using banked samples, and results were not provided to study participants or their physicians. Assessment of thyroid function at 2 time points allowed analysis of weight change in those who were persistently subclinically hypothyroid. We further defined the type of body mass associated with TSH by using DXA, although this was only at a single time point. All of our analyses were adjusted for multiple covariates, including physical activity. We are unable to comment on the relationship between thyroid function and body composition in populations younger than age 65 years. In addition, measurements of thyroid autoantibodies were not performed, so that we were not able to discriminate between individuals with thyroid autoimmunity and those with elevated TSH levels due to other causes. Furthermore, CHS is an observational study, and thus we did not evaluate the effects of treating subclinical hypothyroidism on weight and body composition. In conclusion, our data suggest that subclinical hypothyroidism does not represent an independent risk factor for weight gain in men and women aged 65 and older. There is a cross-sectional relationship between TSH, FT4, weight, and fat mass in older women, but the clinical relevance and directionality of the relationship remains unclear. Intentional weight loss in the elderly remains controversial, and our findings do not support the treatment of subclinical hypothyroidism to prevent weight gain or treat obesity in the elderly.

Acknowledgments Address all correspondence and requests for reprints to: Anne R. Cappola, MD, ScM, Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, 12-136 Translational Research Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104-5160. E-mail: [email protected]. This work was supported by Grant R01AG032317 from the National Institute on Aging (NIA); T32DK007314 from the National Institute of Diabetes, Digestive, and Kidney Disorders; and Contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and Grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contributions from the National Institute of Neurological Disorders and Stroke. Additional support was provided by Grant AG023629 from the NIA. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Disclosure Summary: The authors have nothing to disclose.


1226

Garin et al


References 1. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012; 379:1142–1154. 2. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid. 2000;10:803– 808. 3. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab. 2008;93:S1–S8. 4. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583–2589. 5. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71– 82. 6. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338:1–7. 7. Cohen-Mansfield J, Perach R. Is there a reversal in the effect of obesity on mortality in old age? J Aging Res. 2011;2011:765071. 8. Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005;90:4019 – 4024. 9. Nyrnes A, Jorde R, Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes (Lond). 2006;30:100 –105. 10. Fox CS, Pencina MJ, D’Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med. 2008;168:587–592. 11. Asvold BO, Bjøro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009;94:5023–5027. 12. Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de Gonzalez A. Body fatness and markers of thyroid function among U.S. men and women. PLoS One. 2012;7:e34979. 13. Pinkney JH, Goodrick SJ, Katz J, et al. Leptin and the pituitarythyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. Clin Endocrinol (Oxf). 1998;49:583–588. 14. Alevizaki M, Saltiki K, Voidonikola P, Mantzou E, Papamichael C, Stamatelopoulos K. Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals. Eur J Endocrinol. 2009; 161:459 – 465. 15. Makepeace AE, Bremner AP, O’Leary P, et al. Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers. Clin Endocrinol (Oxf). 2008;69:648 – 652. 16. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–276. 17. Somwaru LL, Arnold AM, Cappola AR. Predictors of thyroid hormone initiation in older adults: results from the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2011;66:809 – 814. 18. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270 –278. 19. Moon MK, Lee YJ, Choi SH, et al. Subclinical hypothyroidism has little influences on muscle mass or strength in elderly people. J Korean Med Sci. 2010;25:1176 –1181. 20. WesterinkJ,vanderGraafY,FaberDR,VisserenFL.Therelationbetween thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. Eur J Clin Invest. 2011;41:159–166. 21. Yeap BB, Alfonso H, Chubb SA, et al. Higher free thyroxine levels are associated with frailty in older men: the Health In Men Study. Clin Endocrinol (Oxf). 2012;76:741–748. 22. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf). 2005;62:487– 491.


23. Ambrosi B, Masserini B, Iorio L, et al. Relationship of thyroid function with body mass index and insulin-resistance in euthyroid obese subjects. J Endocrinol Invest. 2010;33:640 – 643. 24. Díez JJ, Iglesias P. Relationship between thyrotropin and body mass index in euthyroid subjects. Exp Clin Endocrinol Diabetes. 2011; 119:144 –150. 25. Mehran L, Amouzegar A, Delshad H, Azizi F. Association between serum TSH concentration and body mass index in euthyroid subjects: the role of smoking. Arch Iran Med. 2012;15:400 – 403. 26. Zhang J, Sun H, Chen L, et al. Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. J Huazhong Univ Sci Technolog Med Sci. 2012;32:47–52. 27. Souza Ade M, Sichieri R. Relationship between body mass index and thyrotropin in euthyroid women: differences by smoking, race and menopausal status. Obes Facts. 2011;4:175–179. 28. Lai Y, Wang J, Jiang F, et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J. 2011; 58:23–30. 29. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf). 2010;72:696 –701. 30. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol (Oxf). 2006;64: 125–128. 31. Svare A, Nilsen TI, Bjoro T, Asvold BO, Langhammer A. Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clin Endocrinol (Oxf). 2011;74:769 –775. 32. Wang CY, Chang TC, Chen MF. Associations between subclinical thyroid disease and metabolic syndrome. Endocr J. 2012;59:911–917. 33. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. Eur J Clin Invest. 2011;41:1202–1209. 34. Boivin M, Camirand A, Carli F, Hoffer LJ, Silva JE. Uncoupling protein-2 and -3 messenger ribonucleic acids in adipose tissue and skeletal muscle of healthy males: variability, factors affecting expression, and relation to measures of metabolic rate. J Clin Endocrinol Metab. 2000;85:1975–1983. 35. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92: 1715–1723. 36. Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med. 2002;112:348 –354. 37. Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab. 2011;96: E99 –E103. 38. Sari R, Balci MK, Altunbas H, Karayalcin U. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf). 2003;59:258 –262. 39. Chikunguwo S, Brethauer S, Nirujogi V, et al. Influence of obesity and surgical weight loss on thyroid hormone levels. Surg Obes Relat Dis. 2007;3:631– 635; discussion 635– 636. 40. Zimmermann-Belsing T, Brabant G, Holst JJ, Feldt-Rasmussen U. Circulating leptin and thyroid dysfunction. Eur J Endocrinol. 2003; 149:257–271. 41. Toth MJ, Gardner AW, Arciero PJ, Calles-Escandon J, Poehlman ET. Gender differences in fat oxidation and sympathetic nervous system activity at rest and during submaximal exercise in older individuals. Clin Sci (Lond). 1998;95:59 – 66. 42. Isidori AM, Strollo F, Morè M, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab. 2000;85: 1954 –1962.


Subclinical Hypothyroidism and Cardiovascular Disease.

Cognitive function in subclinical hypothyroidism in elderly.

Association between Soluble Klotho and Change in Kidney Function: The Health Aging and Body Composition Study.

Snoring, daytime sleepiness, and incident cardiovascular disease in the health, aging, and body composition study.

Efficacy of a self-directed behavioral health change program: weight, body composition, cardiovascular fitness, blood pressure, health risk, and psychosocial mediating variables.

Subclinical Hypothyroidism.

Cardiovascular Risk Factors in Subclinical Hypothyroidism: A Case Control Study in Nepalese Population.

Physical Activity and Change in Long Distance Corridor Walk Performance in the Health, Aging, and Body Composition Study.

Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with cardiovascular disease.

Measures of Body Size and Composition and Risk of Incident Atrial Fibrillation in Older People: The Cardiovascular Health Study.

Abuse and subclinical cardiovascular disease among midlife women: the study of women's health across the nation.

Change in body mass index, weight, and hot flashes: a longitudinal analysis from the midlife women's health study.

The biochemical prognostic factors of subclinical hypothyroidism.

Management of subclinical hypothyroidism: the thyroidologists' view.

Subclinical hypothyroidism and pregnancy: the intersection of science, the art of medicine, and public health policy.

Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study.

Secular change in cardiorespiratory fitness and body composition of women: the Aerobics Center Longitudinal Study.

Association of body fat composition and obstructive sleep apnea in the elderly: A longitudinal study.

Change in body weight and body image in young adults: a longitudinal study.

The debate on treating subclinical hypothyroidism.

The biochemical prognostic factors of subclinical hypothyroidism.

Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: the subsequent phases of thyroid function in a patient chronically treated with amiodarone.

Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Effects of whole body vibration training on body composition, skeletal muscle strength, and cardiovascular health.